The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.

It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.

[10] In December 2020, the UAE previously announced interim results showing 86% efficacy.

[11] While mRNA vaccines showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks.

[22][23][24] Sinopharm was expected to produce one billion doses of the BIBP vaccine in 2021.